Piper Sandler Reiterates Neutral Rating for Envista (NYSE:NVST)

Posted by Brian Himes on Sep 18th, 2026

Envista (NYSE:NVST – Get Free Report)‘s stock had its “neutral” rating reaffirmed by Piper Sandler in a note issued to investors on Friday, Benzinga reports. They currently have a $28.00 price objective on the stock. Piper Sandler’s price target points to a potential upside of 19.40% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. UBS Group reduced their target price on Envista from $30.00 to $27.00 and set a “neutral” rating for the company in a report on Friday. Morgan Stanley set a $23.00 price objective on shares of Envista in a research note on Thursday, August 6th. Zacks Research upgraded shares of Envista from a “hold” rating to a “strong-buy” rating in a report on Friday, August 7th. Robert W. Baird set a $34.00 price target on shares of Envista in a report on Thursday, August 6th. Finally, Barclays reduced their price target on shares of Envista from $34.00 to $32.00 and set an “overweight” rating for the company in a research report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

Get Our Latest Report on Envista

Envista Price Performance

Shares of NVST stock traded down $0.24 during mid-day trading on Friday, hitting $23.45. 1,224,427 shares of the stock traded hands, compared to its average volume of 2,896,582. Envista has a twelve month low of $18.77 and a twelve month high of $30.42. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of 40.40, a price-to-earnings-growth ratio of 1.19 and a beta of 0.86. The company’s 50-day simple moving average is $27.01 and its 200-day simple moving average is $26.06. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43.

Envista (NYSE:NVST – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.07. The business had revenue of $730.50 million during the quarter, compared to analyst estimates of $716.11 million. Envista had a return on equity of 7.88% and a net margin of 3.33%.The company’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 earnings per share. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. As a group, equities research analysts expect that Envista will post 1.53 earnings per share for the current year.

Insider Transactions at Envista

In other Envista news, SVP Mischa Reis sold 8,000 shares of Envista stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the sale, the senior vice president owned 27,321 shares of the company’s stock, valued at $751,327.50. This trade represents a 22.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NVST. Arrowstreet Capital Limited Partnership increased its position in Envista by 341.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,858,293 shares of the company’s stock worth $72,515,000 after buying an additional 2,210,847 shares during the period. Norges Bank bought a new stake in shares of Envista in the fourth quarter valued at approximately $45,113,000. Wellington Management Group LLP grew its stake in shares of Envista by 2,662.1% in the second quarter. Wellington Management Group LLP now owns 1,686,415 shares of the company’s stock worth $44,437,000 after acquiring an additional 1,625,360 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Envista in the second quarter worth $37,316,000. Finally, Pzena Investment Management LLC bought a new position in Envista during the second quarter worth $30,494,000.

Envista News Roundup

Here are the key news stories impacting Envista this week:

Positive Sentiment: Envista is described as technically oversold after the recent selloff, suggesting that heavy selling pressure may be weakening. Zacks also cited broad upward revisions to earnings estimates, which could support a near-term rebound. Down 12% in 4 Weeks, Here’s Why You Should Buy the Dip in Envista
Positive Sentiment: Zacks highlighted Envista as a potential value opportunity, which may attract investors following the stock’s recent decline. However, the article is based primarily on valuation and factor signals rather than a new company announcement. Should Value Investors Buy Envista Stock?
Neutral Sentiment: Envista’s analyst and investor day materials were published, giving investors additional information on management’s strategy and outlook. The available reports do not identify a major new catalyst or guidance change. Envista Analyst/Investor Day Transcript
Neutral Sentiment: Needham reaffirmed its “hold” rating, indicating that the firm does not see enough near-term upside or downside to change its view. Needham rating report
Negative Sentiment: UBS lowered its price target to $27 from $30 while maintaining a “neutral” rating. Although the revised target remains above the recent market level, the reduction signals more limited expected upside and likely contributed to investor caution. UBS Adjusts Envista Price Target

Envista Company Profile

(Get Free Report)

Envista Holdings Corporation is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral-care professionals.

Envista’s portfolio includes dental imaging and diagnostic systems, digital dentistry and CAD/CAM solutions, dental implants, orthodontic brackets and wires, clear aligner products, endodontic instruments, restorative materials, infection-prevention products and other dental consumables.